A naukri.com initiative
Medium
2w
34
Image Credit: Medium
Investing in Macrocyclic Peptide Discovery
- Therapeutic peptides have broad applications in areas like oncology, inflammation, and infection.
- Traditional linear peptides face limitations like poor stability and low membrane permeability.
- Cyclization of peptides leads to macrocyclic peptides (MCP) which offer improved binding, specificity, and stability.
- MCPs have unique advantages over small molecule drugs and large biologics, such as higher specificity and stability.
- MCP discovery involves synthesizing unique libraries, screening for activity, and optimizing hit compounds.
- Display technologies like mRNA and phage display are commonly used in MCP discovery, but they have limitations in library diversity.
- Startups focusing on diverse library generation, advanced screening, and computational discovery are key players in the MCP discovery field.
- Big pharma firms have a high interest in MCPs, with significant deals being made with MCP discovery companies.
- The peptide therapeutics market is expected to reach $100+ billion by 2033, with MCPs representing a significant portion of this market.
- MCP discovery startups have exit opportunities through acquisitions or IPOs, as evidenced by acquisitions like Ra Pharmaceuticals by UCB Pharma.
Read Full Article
2 Likes
For uninterrupted reading, download the app